Consumer Healthcare Giant Haleon Plunges to 52-Week Low
Haleon shares hit a 52-week low as the company trimmed full-year sales targets to 2.5% amid China import halts and Brazil adjustments.
Stocks · News reference
Haleon Adjusts FY26 Organic Revenue Growth To ~2.5%, High-Single-Digit Adjusted Operating Profit Growth At Constant Currency, Net Interest Of ~£255 Million, Incorporating China Centrum OTC Product Classification Changes And Accelerated Brazil Go-To-Market Model Rollout
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Haleon Commences £500 Million Share Buyback Program
Haleon Cuts Full-Year Organic Revenue Growth Guidance
Haleon has lowered its full-year organic revenue growth outlook to approximately 2.5%, down from its previous forecast of 3% to 5%, citing weaker-than-expected sales in its respiratory health category.